EXAS - יחס שווי שוק להכנסות Exact Sciences Corp

Exact Sciences relies on an efficient courier network for biomaterial collection and government-recognized US laboratories. The primary growth driver is the development of liquid biopsy and new Cologuard tests. On GURU.Markets, the price-to-sales multiple visualizes the business valuation trend, where the final value of 6.20 captures this metric by comparing market capitalization with actual revenue.

Exact Sciences diversification into precision oncology and the expansion of its diagnostic portfolio allow the company to scale revenue while mitigating regulatory risks. By analyzing the price-to-sales ratio, an investor assesses the market value of the business relative to its annual turnover: steady growth of this multiple confirms the company's ability to pass costs onto consumers, whereas sharp deviations signal speculative overheating or hidden stagnation.